Clinical Trial Update: Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating Fiasp (fast-acting insulin aspart) in 670G hybrid closed-loop therapy for type 1 diabetes; study completed with posted results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Fiasp (insulin aspart)

Snippet

Sponsor: Stanford University | Conditions: Diabetes Mellitus, Type 1 | Phase 4 | Status: COMPLETED | Results posted: 2021-08-18